Filing Details

Accession Number:
0001209191-18-046059
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-09 17:00:52
Reporting Period:
2018-08-07
Accepted Time:
2018-08-09 17:00:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1123494 Harvard Bioscience Inc HBIO Laboratory Analytical Instruments (3826) 043306140
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1585223 Jeffrey Duchemin C/o Harvard Bioscience, Inc.
84 October Hill Road
Holliston MA 01746
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-07 100,000 $4.31 890,742 No 4 M Direct
Common Stock Disposition 2018-08-07 100,000 $6.07 790,742 No 4 S Direct
Common Stock Acquisiton 2018-08-08 5,500 $4.31 796,242 No 4 M Direct
Common Stock Disposition 2018-08-08 5,500 $6.35 790,742 No 4 S Direct
Common Stock Acquisiton 2018-08-09 44,500 $4.31 835,242 No 4 M Direct
Common Stock Disposition 2018-08-09 44,500 $6.41 790,742 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.01 Per Share Stock option (right to buy) Disposition 2018-08-07 100,000 $0.00 500,000 $4.31
Common Stock, Par Value $0.01 Per Share Stock option (right to buy) Disposition 2018-08-08 5,500 $0.00 400,000 $4.31
Common Stock, Par Value $0.01 Per Share Stock option (right to buy) Disposition 2018-08-09 44,500 $0.00 394,500 $4.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
400,000 2016-11-18 2023-11-18 No 4 M Direct
394,500 2016-11-18 2013-11-18 No 4 M Direct
350,000 2016-11-18 2023-11-18 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (continued in footnote 3 below)
  3. (continuation of footnote 3 above) (f) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 198,842 shares of common stock held by the Reporting Person.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
  5. Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 98,842 shares of common stock held by the Reporting Person.
  6. Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 104,342 shares of common stock held by the Reporting Person.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).
  8. Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 143,342 shares of common stock held by the Reporting Person.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).